Concert Secures Celgene As Its Latest Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Concert Pharmaceuticals has garnered a third partnership for its deuterium-modification platform as the Massachusetts biotech continues to push its internal pipeline forward on its own.
You may also be interested in...
Jazz And Concert In Tune On Xyrem
The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.
Auspex Secures $25M To Get To NDA
The biotech garnered a $25 million Series D round, which could be enough to propel it through a Phase III trial and to FDA with its lead candidate. Investors are hoping an approved product could make Auspex an attractive take-out candidate.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.